Form 8-K - Current report:
SEC Accession No. 0001404644-25-000029
Filing Date
2025-04-14
Accepted
2025-04-14 16:50:15
Documents
14
Period of Report
2025-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20250414.htm   iXBRL 8-K 32377
2 EX-10.1 ngne_amendmenttobbsidelett.htm EX-10.1 11153
  Complete submission text file 0001404644-25-000029.txt   173559

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20250414.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20250414_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20250414_pre.xml EX-101.PRE 13050
16 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20250414_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 25836538
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)